Global Next Generation Cancer Diagnostics Market to reach USD 26.70 billion by 2026

Chapter 1.	Executive Summary  
1.1.	Market Snapshot
1.2.	Global & Segmental Market Estimates & Forecasts, 2017-2026 (USD Billion)
1.2.1.	Next Generation Cancer Diagnostic Market, by Technology, 2017-2026 (USD Billion)
1.2.2.	Next Generation Cancer Diagnostic Market, by Type, 2017-2026 (USD Billion)
1.2.3.	Next Generation Cancer Diagnostic Market, by Application, 2017-2026 (USD Billion)
1.2.4.	Next Generation Cancer Diagnostic Market, by Function, 2017-2026 (USD Billion)
1.2.5.	Next Generation Cancer Diagnostic Market, by Region, 2017-2026 (USD Billion)
1.3.	Key Trends
1.4.	Estimation Methodology
1.5.	Research Assumption
Chapter 2.	Global Next Generation Cancer Diagnostic Market Definition and Scope 
2.1.	Objective of the Study
2.2.	Market Definition & Scope
2.2.1.	Scope of the Study
2.2.2.	Industry Evolution
2.3.	Years Considered for the Study
2.4.	Currency Conversion Rates
Chapter 3.	Global Next Generation Cancer Diagnostic Market Dynamics	
3.1.	Next Generation Cancer Diagnostic Market Impact Analysis (2018-2026)
3.1.1.	Market Drivers
3.1.2.	Market Challenges
3.1.3.	Market Opportunities
Chapter 4.	Global Next Generation Cancer Diagnostic Market Analysis
4.1.	Porter’s 5 Force Model
4.1.1.	Bargaining Power of Suppliers
4.1.2.	Bargaining Power of Buyers
4.1.3.	Threat of New Entrants
4.1.4.	Threat of Substitutes
4.1.5.	Competitive Rivalry
4.1.6.	Futuristic Approach to Porter’s 5 Force Model (2016-2026)
4.2.	PEST Analysis
4.2.1.	Political 
4.2.2.	Economical
4.2.3.	Social 
4.2.4.	Technological 
4.3.	Investment Adoption Model
4.4.	Analyst Recommendation & Conclusion
Chapter 5.	Global Next Generation Cancer Diagnostic Market by Technology 
5.1.	Market Snapshot 
5.2.	Global Next Generation Cancer Diagnostic Market by Technology, Performance - Potential Analysis
5.3.	Global Next Generation Cancer Diagnostic Market Estimates & Forecasts by Technology 2016-2026 (USD Billion)
5.4.	Next Generation Cancer Diagnostic Market, Sub Segment Analysis 
5.4.1.	NGS-based cancer diagnostics
5.4.2.	qPCR & Multiplexing
5.4.3.	Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
5.4.4.	Protein microarrays-based cancer diagnostics
5.4.5.	DNA microarrays-based cancer diagnostics
Chapter 6.	Global Next Generation Cancer Diagnostic Market, by Type 
6.1.	Market Snapshot 
6.2.	Global Next Generation Cancer Diagnostic Market by Type, Performance - Potential Analysis
6.3.	Global Next Generation Cancer Diagnostic Market Estimates & Forecasts by Type, 2016-2026 (USD Billion)
6.4.	Next Generation Cancer Diagnostic Market, Sub Segment Analysis 
6.4.1.	Lung Cancer
6.4.2.	Breast Cancer 
6.4.3.	Colorectal Cancer 
6.4.4.	Cervical Cancer 
6.4.5.	Others
Chapter 7.	Global Next Generation Cancer Diagnostic Market by Application 
7.1.	Market Snapshot 
7.2.	Global Next Generation Cancer Diagnostic Market by Application, Performance - Potential Analysis
7.3.	Global Next Generation Cancer Diagnostic Market Estimates & Forecasts by Application, 2016-2026 (USD Billion)
7.4.	Next Generation Cancer Diagnostic Market, Sub Segment Analysis
7.4.1.	Biomarker Development
7.4.2.	CTC Analysis 
7.4.3.	Proteomic Analysis
7.4.4.	Epigenetic Analysis
7.4.5.	Genetic Analysis
Chapter 8.	Global Next Generation Cancer Diagnostic Market by Function 
8.1.	Market Snapshot 
8.2.	Global Next Generation Cancer Diagnostic Market by Application, Performance - Potential Analysis
8.3.	Global Next Generation Cancer Diagnostic Market Estimates & Forecasts by Application, 2016-2026 (USD Billion)
8.4.	Next Generation Cancer Diagnostic Market, Sub Segment Analysis
8.4.1.	Therapeutic Monitoring
8.4.2.	Companion Diagnostics
8.4.3.	Prognostic Diagnostics
8.4.4.	Cancer Screening
8.4.5.	Risk Analysis
Chapter 9.	Global Next Generation Cancer Diagnostic Market, Regional Analysis
9.1.	Next Generation Cancer Diagnostic Market, Regional Market Snapshot 
9.2.	North America Next Generation Cancer Diagnostic Market 
9.2.1.	U.S. Next Generation Cancer Diagnostic Market
9.2.1.1.	Technology breakdown estimates & forecasts, 2016-2026
9.2.1.2.	Type breakdown estimates & forecasts, 2016-2026
9.2.1.3.	Application breakdown estimates & forecasts, 2016-2026
9.2.1.4.	Function breakdown estimates & forecasts, 2016-2026
9.2.2.	Canada Next Generation Cancer Diagnostic Market
9.3.	Europe Next Generation Cancer Diagnostic Market Snapshot
9.3.1.	U.K. Next Generation Cancer Diagnostic Market
9.3.2.	Germany Next Generation Cancer Diagnostic Market
9.3.3.	Rest of Europe Next Generation Cancer Diagnostic Market
9.4.	Asia-Pacific Next Generation Cancer Diagnostic Market Snapshot
9.4.1.	China Next Generation Cancer Diagnostic Market 
9.4.2.	India Next Generation Cancer Diagnostic Market 
9.4.3.	Japan Next Generation Cancer Diagnostic Market
9.4.4.	Rest of Asia Pacific Next Generation Cancer Diagnostic Market
9.5.	Latin America Next Generation Cancer Diagnostic Market Snapshot
9.5.1.	Brazil Next Generation Cancer Diagnostic Market
9.5.2.	Mexico Next Generation Cancer Diagnostic Market
9.6.	Rest of The World Next Generation Cancer Diagnostic Market
Chapter 10.	Competitive Intelligence
10.1.	Top Market Strategies
10.2.	Company Profiles
10.2.1.	Abbott
10.2.1.1.	Key Information
10.2.1.2.	Overview
10.2.1.3.	Financial (Subject To Data Availability)
10.2.1.4.	Product Summary
10.2.1.5.	Recent Developments
10.2.2.	Agilent Technologies (Dako)
10.2.3.	Almac Group 
10.2.4.	Cepheid
10.2.5.	F. Hoffmann-La Roche Ltd
10.2.6.	GE Healthcare
10.2.7.	Illumina, Inc.
10.2.8.	Janssen Global Services, LLC
10.2.9.	Koninklijke Philips N.V.
10.2.10.	Novartis AG
10.2.11.	Perkin Elmer, Inc.
10.2.12.	Qiagen 
10.2.13.	Thermo Fisher Scientific, Inc.
Chapter 11.	Research Process
11.1.	Research Process
11.1.1.	Data Mining
11.1.2.	Analysis
11.1.3.	Market Estimation
11.1.4.	Validation
11.1.5.	Publishing
11.2.	Research Attributes
11.3.	Research Assumption

Global Next Generation Cancer Diagnostics Market is valued approximately USD 7.87 billion in 2018 and is expected to grow at 16.5% CAGR during the forecast period of 2019-2026. Next-generation sequencing is utilized as a cancer diagnostic tool for examining genome sequences in cancer. The technique uses numerous technologies for treatment/diagnosis of cancer, including protein microarrays, DNA microarrays and many more. Owing to the early diagnosis and more précised prognosis of various types of cancer, the next generation cancer diagnostics are gaining faster adoption. Also, government measures taken by developed and emerging countries to escalating the number of research projects in accordance with preventative diagnosis are few other factors expected to propel the next-generation cancer diagnostics market growth over the next few years. Moreover, improving healthcare infrastructure in emerging countries along with the development of mass cytometry and the combination of cell-and bead-based flow cytometry technologies are expected to create lucrative growth prospected to the market growth over the forecast period. However, high capital investments & low benefit-cost ratio for biomarkers and limited availability of skilled professionals are few factors obstructing the growth of the global next generation cancer diagnostics market over the forecast period.
The regional analysis of Global next generation cancer diagnostics market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share due to well-established health infrastructure along with favorable government initiatives present in the region. However, Asia-Pacific is anticipated to exhibit higher growth rate/CAGR owing to rising prevalence of cancer among people and rising medical tourism in the region over the forecast period 2019-2026.
The leading player of the market included in this report are:
Abbott
Agilent Technologies (Dako)
Almac Group
Cepheid
F. Hoffmann-La Roche Ltd
GE Healthcare
Illumina, Inc.
Janssen Global Services, LLC
Koninklijke Philips N.V.
Novartis AG
Perkin Elmer, Inc.
Qiagen
Thermo Fisher Scientific, Inc.
The objective of the study is to define market sizes of different segments & countries in previous years and to forecast the values to the next eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as drivers & restraining factors which will define the future growth of the market. Additionally, it will also incorporate the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the global infertility treatment market are given below:
By Technology:
NGS-based cancer diagnostics
qPCR & Multiplexing
Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
Protein microarrays-based cancer diagnostics
DNA microarrays-based cancer diagnostics
By Type:
Lung Cancer
Breast Cancer
Colorectal Cancer
Cervical Cancer
Others
By Applications:
Biomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis
By Functions:
Therapeutic Monitoring
Companion Diagnostics
Prognostic Diagnostics
Cancer Screening
Risk Analysis
Regions:
North America
U.S.
Canada
Europe
UK
Germany
France
Asia Pacific
China
India
Japan
Rest of the World
Furthermore, the years considered for the study are as follows:
Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026
Target Audience of the Next Generation Cancer Diagnostics Market Study
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors